Gynecologic Cancers | Topics

Cancer Vaccine VB10.16 Plus Atezolizumab Yields Promising Responses in HPV16+ Advanced Cervical Cancer
May 10, 2022

Patients with advanced human papillomavirus 16–positive cervical cancer appear to benefit from treatment with VB10.16 and atezolizumab.

Stereotactic Hypofractionated Radiation Therapy Well Tolerated in Uterine Cancer
May 09, 2022

The phase 1/2 SPARTACUS trial assessed the use of stereotactic hypofractionated radiation therapy in patients with uterine cancer; the treatment appeared to be well tolerated.

European Commission Approves Pembrolizumab Plus Chemotherapy With or Without Bevacizumab for Cervical Cancer
May 03, 2022

Patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 can receive treatment with pembrolizumab plus chemotherapy with or without bevacizumab following approval by the European Commission.

Marina Frimer, MD, Talks Future Treatments in Uterine Cancer
April 19, 2022

Marina Frimer, MD, spoke about what the future holds for the treatment of patients with platinum-sensitive recurrent uterine cancer.

NG-641 Plus Nivolumab to be Assessed in Previously Treated Metastatic or Advanced Epithelial Tumors
April 13, 2022

The safety and efficacy of NG-641 plus nivolumab will be assessed as part of the phase 1a/b NEBULA trial in patients with previously treated metastatic or advanced epithelial tumor.

ZN-c3 Yields Promising Preliminary Results in Recurrent/Advanced Uterine Serous Carcinoma
April 12, 2022

Patients with advanced or recurrent uterine serous carcinoma derived promising benefit from treatment with ZN-c3.

Marina Frimer, MD, Discusses Maintenance Niraparib in Platinum-Sensitive Uterine Serous Cancer
March 31, 2022

Marina Frimer, MD, spoke about the goals of a phase 2 trial and how it can impact patients with platinum-sensitive recurrent uterine serous carcinoma.

Addition of Durvalumab to CRT Did Not Significantly Improve PFS vs CRT Alone in Locally Advanced Cervical Cancer
March 25, 2022

Patients with locally advanced cervical cancer did not see further benefit from the addition of concurrent durvalumab to chemoradiotherapy.

Matulonis Provides Overview of Gynecologic Treatment Landscape Advances
March 11, 2022

“Team science is important for being open-minded [and] thinking outside of the box.”

Cemiplimab Achieves Promising Survival in Recurrent Cervical Cancer
February 14, 2022

Patients with recurrent cervical cancer appeared to achieve a promising survival benefit following treatment with cemiplimab.